197 related articles for article (PubMed ID: 10363974)
1. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
Zaharevitz DW; Gussio R; Leost M; Senderowicz AM; Lahusen T; Kunick C; Meijer L; Sausville EA
Cancer Res; 1999 Jun; 59(11):2566-9. PubMed ID: 10363974
[TBL] [Abstract][Full Text] [Related]
2. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Schultz C; Link A; Leost M; Zaharevitz DW; Gussio R; Sausville EA; Meijer L; Kunick C
J Med Chem; 1999 Jul; 42(15):2909-19. PubMed ID: 10425100
[TBL] [Abstract][Full Text] [Related]
3. A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.
Sims PA; Wong CF; McCammon JA
J Med Chem; 2003 Jul; 46(15):3314-25. PubMed ID: 12852762
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
5. Discovery of cyclin-dependent kinase inhibitor, CR229, using structurebased drug screening.
Kim MK; Min J; Choi BY; Lim H; Cho YH; Lee CH
J Microbiol Biotechnol; 2007 Oct; 17(10):1712-6. PubMed ID: 18156791
[TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase.
Kaiser A; Nishi K; Gorin FA; Walsh DA; Bradbury EM; Schnier JB
Arch Biochem Biophys; 2001 Feb; 386(2):179-87. PubMed ID: 11368340
[TBL] [Abstract][Full Text] [Related]
7. [Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study].
Damiens E; Meijer L
Pathol Biol (Paris); 2000 Apr; 48(3):340-51. PubMed ID: 10858966
[TBL] [Abstract][Full Text] [Related]
8. Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential.
Lahusen T; De Siervi A; Kunick C; Senderowicz AM
Mol Carcinog; 2003 Apr; 36(4):183-94. PubMed ID: 12669310
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
[TBL] [Abstract][Full Text] [Related]
10. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.
Song Y; Kesuma D; Wang J; Deng Y; Duan J; Wang JH; Qi RZ
Biochem Biophys Res Commun; 2004 Apr; 317(1):128-32. PubMed ID: 15047157
[TBL] [Abstract][Full Text] [Related]
12. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol.
Knockaert M; Lenormand P; Gray N; Schultz P; Pouysségur J; Meijer L
Oncogene; 2002 Sep; 21(42):6413-24. PubMed ID: 12226745
[TBL] [Abstract][Full Text] [Related]
13. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases.
Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L
Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo.
Wirger A; Perabo FG; Burgemeister S; Haase L; Schmidt DH; Doehn C; Mueller SC; Jocham D
Anticancer Res; 2005; 25(6B):4341-7. PubMed ID: 16309238
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cancer cell growth by cyclin dependent kinase 4 inhibitors synthesized based on the structure of fascaplysin.
Mahale S; Aubry C; Jenkins PR; Maréchal JD; Sutcliffe MJ; Chaudhuri B
Bioorg Chem; 2006 Oct; 34(5):287-97. PubMed ID: 16904725
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition.
Gussio R; Zaharevitz DW; McGrath CF; Pattabiraman N; Kellogg GE; Schultz C; Link A; Kunick C; Leost M; Meijer L; Sausville EA
Anticancer Drug Des; 2000 Feb; 15(1):53-66. PubMed ID: 10888036
[TBL] [Abstract][Full Text] [Related]
17. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
18. ATP-site directed inhibitors of cyclin-dependent kinases.
Gray N; Détivaud L; Doerig C; Meijer L
Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
[TBL] [Abstract][Full Text] [Related]
19. High-resolution crystal structures of human cyclin-dependent kinase 2 with and without ATP: bound waters and natural ligand as guides for inhibitor design.
Schulze-Gahmen U; De Bondt HL; Kim SH
J Med Chem; 1996 Nov; 39(23):4540-6. PubMed ID: 8917641
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Sausville EA; Zaharevitz D; Gussio R; Meijer L; Louarn-Leost M; Kunick C; Schultz R; Lahusen T; Headlee D; Stinson S; Arbuck SG; Senderowicz A
Pharmacol Ther; 1999; 82(2-3):285-92. PubMed ID: 10454206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]